AKT1 and non-Hodgkin lymphoma: Signaling by the PI3K/AKT/mTOR pathway is frequently deregulated in NHL, prompting evaluation of the rapamycin-analog (rapalog) or mTOR inhibitors in multiple clinical trials [4].